SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

DiaMedica Therapeutics Enrolls 200th Patient in Phase 2/3 Stroke Trial

DiaMedica Therapeutics said the 200th patient has enrolled in its REMEDY2 Phase 2/3 acute ischemic stroke trial.

DMAC

Related stories